Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients

P. L. Zinzani, F. Gherlinzoni, S. Storti, A. Zaccaria, E. Pavone, L. Moretti, P. Gentilini, L. Guardigni, A. De Renzo, P. P. Fattori, B. Falini, V. M. Lauta, D. Mannina, F. Zaja, P. Mazza, E. Volpe, F. Lauria, E. Aitini, F. Ciccone, M. TaniV. Stefoni, L. Alinari, M. Baccarani, S. Tura

Research output: Contribution to journalArticle

Abstract

Background: Among the third-generation chemotherapy regimens specifically adapted in the last decade for elderly aggressive non-Hodgkin's lymphoma (NHL) patients, we designed an 8-week cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin and prednisone (VNCOP-B) plus granulocyte colony-stimulating factor (G-CSF) regimen which, in a national multicenter trial, induced good complete response (CR) and relapse-free survival rates with only moderate toxic effects. Here we report a prospective, multicenter, randomized trial comparing the efficacy and toxicity of 8- and 12-week regimens of VNCOP-B plus G-CSF. Patients and methods: From February 1996 to June 2001, 306 consecutive previously untreated stage II-IV aggressive NHL patients ≥60 years of age were enrolled from 12 Italian cooperative institutions. Of the 297 evaluable patients, 149 and 148 received 8- and 12-week regimens, respectively, of VNCOP-B. Results: The CR rates were 63% and 56% in the 8- and 12-week groups; at a median of 32 months (range 3-62 months), relapse-free survival rates were 59% and 55%, respectively. Hematological and non-hematological toxicities were similar in both treatment groups. Conclusions: Our data show that extending induction treatment with the VNCOP-B plus G-CSF regimen from 8 to 12 weeks does not raise the CR rate or provide a more durable remission.

Original languageEnglish
Pages (from-to)1364-1369
Number of pages6
JournalAnnals of Oncology
Volume13
Issue number9
DOIs
Publication statusPublished - Sep 2002

Keywords

  • Aggressive non-Hogdkin's lymphoma
  • Elderly patients
  • Granulocyte colony-stimulating factor
  • VNCOP-B regimen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients'. Together they form a unique fingerprint.

  • Cite this

    Zinzani, P. L., Gherlinzoni, F., Storti, S., Zaccaria, A., Pavone, E., Moretti, L., Gentilini, P., Guardigni, L., De Renzo, A., Fattori, P. P., Falini, B., Lauta, V. M., Mannina, D., Zaja, F., Mazza, P., Volpe, E., Lauria, F., Aitini, E., Ciccone, F., ... Tura, S. (2002). Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Annals of Oncology, 13(9), 1364-1369. https://doi.org/10.1093/annonc/mdf208